Lv21
148 积分 2026-05-19 加入
P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC
22天前
已完结
P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC
1个月前
已完结
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines
3个月前
已完结
Flow Cytometry Method Validation Protocols
3个月前
已完结
How to Design and Validate a Clinical Flow Cytometry Assay
3个月前
已完结
Clinical trials and new therapies in Sjögren’s disease
3个月前
已完结
皖公网安备34019202002308
